Shearman & Sterling represented J.P. Morgan, Morgan Stanley and BNP Paribas as joint book-running managers and representatives of the underwriters in connection with Amgen’s registered $1 billion notes offering, consisting of 3.2% senior notes due 2027. Amgen is a global biotechnology company that discovers, develops, manufactures and delivers human therapeutics based on advances in cellular and molecular biology.

The Team